<DOC>
	<DOCNO>NCT02630043</DOCNO>
	<brief_summary>The purpose research study evaluate investigational drug ( Tolcapone ) alone combination oxaliplatin , relapse refractory neuroblastoma . Tolcapone approve U.S. Food Drug Administration ( FDA ) adult , investigational drug study approve pediatrics indication . Oxaliplatin , although drug approve FDA cancer , investigational treatment neuroblastoma study . This study look safety tolerability tolcapone combination oxaliplatin well tumor response study drug .</brief_summary>
	<brief_title>Trial Tolcapone With Oxaliplatin Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Tolcapone</mesh_term>
	<criteria>1 . Age : ≤ 21 year time study entry . 2 . Diagnosis : Histologic verification either time original diagnosis relapse neuroblastoma . 3 . Disease Status : Patients must ONE following : Any episode recurrent disease follow completion aggressive multidrug frontline therapy . Any episode progressive disease aggressive multidrug frontline therapy . Primary resistant/refractory disease detect conclusion least 4 cycle aggressive multidrug induction chemotherapy accord highrisk neuroblastoma protocol . 4 . Measurable evaluable disease , include least one following : measureable tumor CT MRI ; positive MIBG , PET scan ; positive bone marrow biopsy/aspirate . 5 . Current disease state must one currently know curative therapy 6 . A negative urine serum pregnancy test require female subject child bear potential ( onset menses ≥13 year age ) . 7 . Organ Function Requirements : Subjects must adequate liver function define : AST ALT ≤ upper limit normal Serum bilirubin must ≤ 2.0 mg/dl Subjects must adequate Bone Marrow function define : For patient without bone marrow involvement : • Peripheral absolute neutrophil count ( ANC ) &gt; 750/uL Subjects must adequate renal function Both male female postpubertal study subject need agree use one effective birth control method treatment 90 day treatment stop . These method include total abstinence ( sex ) , oral contraceptive ( `` pill '' ) , intrauterine device ( IUD ) , levonorgestrol implant ( Norplant ) , medroxyprogesterone acetate injection ( Depoprovera shot ) . If one use , contraceptive foam condom recommend . Informed Consent : All subject and/or legal guardian must sign informed write consent . Assent , appropriate , obtain accord institutional guideline . Lansky score &lt; 50 % BSA ( m2 ) &lt; 0.5 Prior Therapy Patients must fully recover acute toxic effect prior anti cancer chemotherapy within follow timeline : Myelosuppressive chemotherapy : Must receive within 2 week enrollment onto study ( 6 week prior nitrosourea ) . Hematopoietic growth factor : At least 5 day since completion therapy growth factor . Biologic ( antineoplastic agent ) : At least 7 day since completion therapy biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss Study Chair . Immunotherapy : At least 6 week since completion type immunotherapy , e.g . tumor vaccine . Monoclonal antibody : At least 7 day 3 halflives , whichever longer , must elapse since prior treatment monoclonal antibody . XRT : At least 14 day since last treatment except radiation deliver palliative intent nontarget site . Stem Cell Transplant Rescue : No evidence active graft vs. host disease ≥ 2 month must elapse since transplant . Investigational Drugs : Subjects receive another investigational drug within last 14 day exclude participation . Subjects CNS lesion exclude Subjects history depression , anxiety , psychotic disorder ( due tolcapone adverse event profile ) . Subjects pregnant breastfeed infant . Subjects swallow tablet . Infection : Subjects uncontrolled infection eligible infection judge well controlled opinion investigator . Subjects , opinion investigator , may able comply safety monitoring requirement study , compliance likely suboptimal , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>